Prasco Laboratories, a US-based privately held healthcare company, announced on Friday that it has introduced the Authorised Generic of ZIOPTAN (tafluprost ophthalmic solution) 0.0015% in collaboration with US-based Thea Pharma, Inc., an independent pharmaceutical company.
The product is therapeutically equivalent to ZIOPTAN, marketed under the Prasco label, and will be widely offered in United States pharmacies. It is a prostaglandin analogue intended to decrease elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Prasco chief executive officer, Chris Arington, said, 'This partnership with Théa expands our ophthalmic portfolio, giving patients greater access and affordability to critical prescriptions they need.'
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US